Greetings and welcome to the Biomx third quarter, 2024 financial results conference call (Operator Instructions) It is now my pleasure to introduceMarina Wolfson, Chief Financial Officer. Thank you.
SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB: EVFM) today announced financial results for the third quarter and ...
"As the only oral penem antibiotic approved for commercial sale in the U.S. and the potentially first branded uncomplicated urinary tract infection (uUTI) product to enter this underserved market in ...
Research and development (R&D) expenses for the third quarter 2024 were $3.1 million compared to $14.9 million for the same period in 2023. The decrease for the three-month period was primarily due to ...
November 13, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of ...
(Mandavilli, 11/12) NBC News: Decrease In Syphilis Diagnoses Among Gay Men Most Likely Linked To Preventive Antibiotic Use And importantly, diagnoses of primary and secondary syphilis — the most ...
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, ...